Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

被引:113
|
作者
Freites Nunez, Dalifer D. [1 ,2 ]
Leon, Leticia [1 ,2 ,3 ]
Mucientes, Arkaitz [1 ,2 ]
Rodriguez-Rodriguez, Luis [1 ,2 ]
Font Urgelles, Judit [4 ]
Madrid Garcia, Alfredo [1 ,2 ]
Colomer, Jose, I [1 ,2 ]
Jover, Juan A. [4 ,5 ]
Fernandez-Gutierrez, Benjamin [4 ]
Abasolo, Lydia [1 ,2 ]
机构
[1] Fdn Invest Biomed Hosp Clin San Carlos, Rheumatol Dept, Madrid, Spain
[2] Fdn Invest Biomed Hosp Clin San Carlos, IDISSC, Madrid, Spain
[3] Univ Camilo Jose Cela, Dept Hlth & Educ, Madrid, Spain
[4] Hosp Clin San Carlos, Rheumatol Dept, Madrid, Spain
[5] Univ Complutense Madrid, Med Dept, Madrid, Comunidad De Ma, Spain
关键词
CORONAVIRUS;
D O I
10.1136/annrheumdis-2020-217984
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19. Methods An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission. Results The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3-10) days. The median length of stay was 9 (6-14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model. Conclusion Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.
引用
收藏
页码:1393 / 1399
页数:7
相关论文
共 50 条
  • [21] Correspondence to 'Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases'
    Wu, Bo-Yao
    Chan, Chi-Ho
    Wei, James Cheng-Chung
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (12)
  • [22] COVID-19 and inflammatory rheumatic diseases
    Hasseli, Rebecca
    Ladner, Ulf Muller
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2021, 146 (23) : 1564 - 1568
  • [23] COVID-19 in Italian patients with rheumatic autoimmune systemic diseases
    Ferri, Clodoveo
    Giuggioli, Dilia
    Raimondo, Vincenzo
    Fallahi, Poupak
    Antonelli, Alessandro
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (09)
  • [24] The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
    Rorat, Marta
    Zarebska-Michaluk, Dorota
    Kowalska, Justyna
    Kujawa, Krzysztof
    Rogalska, Magdalena
    Kozielewicz, Dorota
    Lorenc, Beata
    Sikorska, Katarzyna
    Czupryna, Piotr
    Bolewska, Beata
    Maciukajc, Jadwiga
    Piekos, Tomasz
    Podlasin, Regina
    Dworzanska, Anna
    Mazur, Wlodzimierz
    Brzdek, Michal
    Szymanek-Pasternak, Anna
    Flisiak, Robert
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (24)
  • [25] Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19
    Vlachoyiannopoulos, Panayiotis G.
    Magira, Eleni
    Alexopoulos, Haris
    Jahaj, Edison
    Theophilopoulou, Katerina
    Kotanidou, Anastasia
    Tzioufas, Athanasios G.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (12) : 1661 - +
  • [26] Factors influencing the course of COVID-19 in the inflammatory rheumatic diseases
    Celik, S.
    Kutu, M. E.
    Bal, C.
    Karadeniz, B.
    Atagunduz, P.
    Soy, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (03) : 758 - 759
  • [27] COVID-19 and systemic autoimmune rheumatic diseases
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2021, 3 (02): : E100 - E100
  • [28] Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases
    Yap, Ruth Xian Lynn
    Lai, Yi Wye
    Wei, Chang
    Ng, Joel Jia Wei
    Xu, Dan
    Feng, Shuo
    Mu, Rong
    Thong, Bernard Yu-Hor
    Xu, Chuanhui
    VACCINES, 2024, 12 (03)
  • [29] Prevalence and Risk Factors of Postacute Sequelae of COVID-19 in Adults With Systemic Autoimmune Rheumatic Diseases
    Teles, Mayan S.
    Brundage, Janetta
    Chiang, Teresa Po-Yu
    Alejo, Jennifer L.
    Henriquez, Nicolas
    Wallwork, Rachel
    Christopher-Stine, Lisa
    Massie, Allan
    Segev, Dorry L.
    Connolly, Caoilfhionn M.
    Paik, Julie J.
    Werbel, William A.
    JOURNAL OF RHEUMATOLOGY, 2024, 51 (09) : 928 - 933
  • [30] COVID-19 IN RITUXIMAB TREATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES
    Hasseli, R.
    Hoyer, B. F.
    Lorenz, H. M.
    Pfeil, A.
    Regierer, A.
    Richter, J.
    Schmeiser, T.
    Strangfeld, A.
    Voll, R.
    Schulze-Koops, H.
    Krause, A.
    Specker, C.
    Mueller-Ladner, U.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 957 - 957